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Abstract
Seventh tumor-node-metastasis (TNM) classification for 
gastric cancer, published in 2010, introduced changes 
in all of its three parameters with the aim to increase 
its accuracy in prognostication. The aim of this review 
is to analyze the efficacy of these changes and their 
implication in clinical practice. We reviewed relevant 
Literature concerning staging systems in gastric cancer 
from 2010 up to March 2016. Adenocarcinoma of 
the esophago-gastric junction still remains a debated 
entity, due to its peculiar anatomical and histological 
situation: further improvement in its staging are 
required. Concerning distant metastases, positive 
peritoneal cytology has been adopted as a criterion 
to define metastatic disease: however, its search 
in clinical practice is still far from being routinely 
performed, as staging laparoscopy has not yet reached 
wide diffusion. Regarding definition of T and N: in 
the era of multimodal treatment these parameters 
should more influence both staging and surgery. The 
changes about T-staging suggested some modifications 
in clinical practice. Differently, many controversies 
on lymph node staging are still ongoing, with the 
proposal of alternative classification systems in order 
to minimize the extent of lymphadenectomy. The next 
TNM classification should take into account all of these 
aspects to improve its accuracy and the comparability 
of prognosis in patients from both Eastern and Western 
world.
Key words: Gastric cancer; Staging system; Tumor-
node-metastasis; Prognostic factors; Clinical practice
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
MINIREVIEWS
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.3748/wjg.v22.i34.7748
World J Gastroenterol  2016 September 14; 22(34): 7748-7753
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2016 Baishideng Publishing Group Inc. All rights reserved.
7748 September 14, 2016|Volume 22|Issue 34|WJG|www.wjgnet.com
evaluated on PubMed Central with combination of 
following MESH terms: gastric cancer and staging 
system, gastric cancer and TNM, esophago-gastric 
junction and staging, gastric cancer and distant 
metastasis. All abstracts were read separately by two 
different surgeons belonging to an Italian University 
Hospital, and scientific relevance of papers has been 
assessed mostly according to originality of the article, 
accuracy of the statistical method and number of 
patients. All of the selected papers were fully read 
by two or more surgeons, and only papers reported 
in References have been judged clinically and 
scientifically relevant.
ADENOCARCINOMA OF ESOPHAGO-
GASTRIC JUNCTION
Latest TNM classification made an effort to clarify 
recommendations about malignancies arising at or 
close to the esophago-gastric junction. According to 
anatomical criteria consistent with the 5-cm rule of 
Siewert Classification[3], seventh TNM classification 
included esophago-gastric junction tumor in the 
esophageal chapter[4]. Unfortunately, this proposal 
might lead to classify as esophageal a tumor of 
the gastric fundus[5]. Hence, most Adenocarcinoma 
of esophago-gastric junction (AEGs), including 
adenocarcinomas of the cardia and subcardia, are 
now to be staged as esophageal adenocarcinomas 
rather than gastric cancers, although they actually 
originate from the gastric mucosa and consequently 
have different biological properties compared with 
genuine gastric and genuine esophageal cancers[6]; 
therefore cardia tumors still remain in a no-man’s land 
of staging.
Actually, the esophago-gastric junction is a 
peculiar transitional area from squamous to glandular 
epithelium, which is different from epithelium of distal 
stomach. Concerning macroscopic anatomy, the intra-
abdominal part of the esophagus, esophagogastric 
junction, and fundus are not totally covered by visceral 
peritoneum. These portions of the stomach are 
located extraperitoneally or retroperitoneally, which 
makes AEG more prone to infiltrate the serosa and 
more inclined to peritoneal metastasis; moreover, a 
different pathway of lymphatic metastases has to be 
considered[7].
These anatomical differences related to the eso-
phago-gastric junction imply a different oncological 
management as well as a different surgical approach 
than gastric or esophageal cancer: basically, the 
clinicians should early know the correct strategy and a 
reliable prognosis to present to their patients.   
Although some authors reported better progno-
stication when AEG Ⅱ/Ⅲ tumors were staged as gastric 
cancer[8,9], several studies advocate the introduction 
of a separate staging system for neoplasm of this 
“damned” anatomical district, as neither the esophageal 
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Core tip: After five years since latest tumor-node-
metastasis (TNM) classification for gastric cancer 
staging has been published, we reviewed Literature 
concerning its accuracy in prognostication and the 
impact on clinical practice of the statements introduced 
in 2010. While waiting for the next UICC/AJCC TNM 
classification for gastric cancer, open issues and new 
proposals are also critically discussed.
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INTRODUCTION
Gastric cancer is the fifth most common malignancy 
and the third leading cause of cancer-related death[1]. 
In the era of stage adapted therapy, where effective 
tools both in preoperative staging and in peri-opera-
tive treatment (neoadjuvant and adjuvant therapy) 
are widely available, the importance of an accurate 
prognostication is crucial for the best possible manage-
ment of gastric cancer patients.
A cancer staging system should describe the 
severity of a neoplasm according to the extent of 
primary tumor and of its spread, both local and distant; 
this allows clinicians to calculate prognosis, to compare 
groups of patients, and to determine the treatment 
strategy. As it should be used in an everyday clinical 
practice setting, an ideal cancer staging system has to 
be easily reproducible and applicable, both before and 
after treatment. 
Since its first application in the staging of gastric 
malignancies in 1974[2], the tumor-node-metastasis 
(TNM) staging system has been periodically modified, 
in order to ameliorate its accuracy in stratification of 
prognosis in gastric cancer patients.
The current TNM system for gastric cancer, although 
still improvable, well fulfills the above mentioned 
requirements. 
In last five years different Authors analyzed usefu­
lness of the seventh TNM classification and, up to 
now, it seems that different issues still require further 
improvements.
In this review, we summarize current opinions and 
controversies on the seventh classification of the TNM 
staging system for gastric cancer, introducing open 
questions and new issues which may integrate the 
traditional way of staging.
LITERATURE RESEARCH
Recent Literature (from 2010 up to March 2016) was 
nor the gastric staging scheme could well stratify the 
prognosis of these patients[10-12]. 
Staging of tumors arising from the esophagogastric 
junction should require further revision.
Distant metastasis (M)
Regarding assessment of M parameter, Mx has been 
deleted. To be correct, the lack of information about 
status of anatomical districts far from primary tumor 
site must be considered as inappropriate. 
In every day clinical practice, it means that an 
accurate staging process must be performed (both 
before and after treatment); this again, became even 
more important, since latest TNM classification included 
findings of positive peritoneal cytology (as well as 
omental tumor not part of continuous extension) in M1 
category[4]. 
After more than five years since this proposal, 
unfortunately, clinical practice has not been really 
modified: in fact, the routinely use of laparoscopic 
staging, which allows both retrieval of free fluid 
for cytologic examination and inspection of the 
entire peritoneal cavity, and thus eventual omental 
implants[5,13], has not reached a wide diffusion yet[14]. 
This “bad habit” is responsible for understaging of 
disease or useless laparotomies in about 20% of 
cases[15,16]. 
Moreover, since some studies reported outcomes 
of potentially curative resections after the clearance 
of peritoneal cytology (conversion from positive to 
negative after neoadjuvant chemotherapy)[17,18], it 
might be responsible of sub-optimal treatment.
Actually, a standardization of the method used to 
perform peritoneal cytology is needed: in fact, different 
rates of positive cases with different techniques have 
been reported: > 20% on a routine cytology, 35% on 
immunohistochemistry and 50% on RT-PCR in cases of 
a serosa invasion-positive gastric carcinoma[19].
This new change in the last TNM classification could 
be considered an improvement according to prognostic 
results. Nevertheless, it should suggest a more reliable 
compliance to clinicians.
Node (N)
The cut off of metastatic regional lymph nodes in 
the N category was changed, too (N1 = 1-2 nodes; 
N2= 3-6 nodes; N3a= 7-15 nodes; N3b= more 
than 15 nodes)[4]. Moreover, the minimum number 
of required nodes reached 16, although this seems 
to be in contrast with the sentence (added in the 
previous edition) which allows to classify as pN0 also 
negative nodes tumors even if the minimum number 
of examined nodes is not met. This proposal seems to 
derive from the need to minimize non­homogeneity in 
the extent of lymphadenectomy.
Actually, lymph node staging is the main object 
of current controversies in TNM staging system. In 
last years, different authors compared the prognostic 
power between the sixth and the seventh TNM 
classification, as well as they proposed possible 
alternative staging systems.
According to comparison studies, seventh TNM 
classification for gastric cancer provided a more 
detailed classification of prognosis than the sixth 
system[20,21]. With specific regard to the proposal of 
new staging criteria, lymph node ratio (LNR) gained 
increasing popularity. It is defined as the ratio between 
the number of positive nodes and the number of total 
examined nodes. Most studies concluded that LNR is 
superior to the traditional N stage in TNM system in 
stratifying the prognosis of gastric cancer patients[22-28]. 
LNR, and other alternative node staging system, such 
as LODDs (log of the ratio between the probability 
of being a positive lymph node and the probability of 
being a negative lymph node when one lymph node is 
retrieved)[29], have been proposed especially in groups 
of patients with less than 15 retrieved nodes: thus, it 
seems that most of the attempts are made to justify 
a suboptimal surgery about lymphadenectomy, rather 
than to increase prognostic power of pathological 
lymph node staging[30,31].
In this context, a possible further staging improve-
ment could be to associate LNR (instead of the more 
complex LODDs) with the last numeric criterion.
Tumor (T)
Regarding the T parameter, latest TNM classification 
has introduced high grade displasia (HGD) in Tis 
category; T1 category has been subdivided into 
T1a (tumors involving lamina propria or muscularis 
mucosae) and T1b (tumors involving submucosa), and 
T2b has been replaced with new T3 category, so that 
serosal involvement is now considered a T4 tumor (T4a 
category differently from T4b category assigned to 
tumors invading adjacent structures)[4].
Inclusion of HGD in Tis category lead to a more 
aggressive approach to this histologic entity. According 
to latest Japanese guidelines for gastric cancer[32], 
some histologic and dimensional criteria have to be 
met in order to perform endoscopic mucosal resection 
(EMR) or endoscopic submucosal dissection: therefore, 
preoperative diagnosis has to be even more accurate. 
Furthermore, as distinguishing invasive carcinoma 
from HGD in gastric biopsy specimens is not always 
possible, EMR can also be proposed in order to obtain 
a more accurate histologic definition[33].
Finally, new T3 category implied for the first time 
the definition of locally advanced disease for a tumor 
entirely contained into the gastric wall. As subserosal 
involvement may not be correctly evaluated during 
staging laparoscopy, EUS - which remains the first-
choice imaging modality in preoperative T staging of 
gastric cancer - emerges again as a crucial step in pre-
treatment staging[34]. Nonetheless, it is not always 
included in staging algorithm. De facto, although 
trial about perioperative chemotherapy have been 
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disease, and a good instrument in everyday clinical 
practice.
The International Gastric Cancer Association 
(IGCA) launched in 2009 a staging project with the 
aim of collecting gastric cancer data worldwide, in 
order to formulate a contemporary evidence based 
classification. This project collected data from 59 
Institutions in 15 Countries and used them to validate 
the latest TNM classification: for both T and N it 
accepted the categories of the seventh TNM and 
then assessed a new stage grouping scheme (Table 
1), which better stratifies prognosis also in patients 
with Siewert type Ⅱ or Ⅲ tumor. A relevant aspect 
of this new staging system is the split between N3a 
and N3b categories, derived from finding of worse 
survival in patients with more of 6 involved nodes. 
This new scheme could be introduced in next TNM 
classification[29] along with some implications of the 
above mentioned considerations: hence, this next 
staging solution, tested with data from both Eastern 
and Western patients, should allow to appropriately 
compare treatment results in different regions. 
If the IGCA staging system at the moment does 
not add any new parameter, other Authors reflected 
on possible introduction of more details to improve 
accuracy of prognostication.
As specified, the role of LNR seems to be quite 
widely accepted, but other issues regarding lymph 
node involvement are still debated, such as the 
presence of isolated tumor cells, now classified as 
pN0(i+), which might be classified as pN1(i+), and 
the extra capsular extension of regional metastasis in 
adjacent tissues[39].
Again, lymphatic and venous invasion have been 
proposed for a better definition of T category[40], as 
well as the possible use of molecular findings (i.e., 
HER2), but it is still to determine whether these data 
should be actually introduced in the TNM staging 
system or they should be considered as additional (and 
thus optional) prognostic factors.
In conclusion, further improvements are obviously 
needed, but if on one hand the integration with 
molecular and histopathological findings may give 
more precision to prognosis prediction, on the other 
hand it will certainly reduce the easy applicability of 
the staging scheme[39].
Without any doubt we are going toward a more 
specific and precise staging system, and this requires 
strict statistical evaluations. While waiting for the 
perfect staging system, we should at first reach stan­
dardization of both surgical (use of staging laparoscopy, 
extent of resection, proper lymphadenectomy) and 
pathological technique (blocks of primary tumor, nodes 
count accuracy, immunoistochemistry of lymph nodes 
to detect isolated tumor cells, technique for peritoneal 
cytology), so that the future TNM classification will not 
be conditioned by the need of supply to inadequate 
surgery and/or inadequate pathological staging.
conducted even on T2 tumors[35], at the moment T3 is 
often excluded from perioperative treatment strategy.
The change of Tis and T1 categories simplified the 
(endoscopic) management of early cancers. Even if 
the change of T3 category did not imply significant 
publications on the comparison between the sixth and 
the seventh TNM classification, in the future revisions 
it could be useful to reconsider a simplification of the 
staging related to the deep involvement of stomach 
wall.
GROUP STAGING
Finally, the aforementioned revisions of the three 
parameters also resulted in a rearrangement of stage 
grouping. The most important feature in latest TNM 
is that only distant metastasis defines stage Ⅳ (very 
poor prognosis)[4]; this means that T4 and N3 are not 
necessarily considered signs of significantly advanced 
disease anymore. This could probably have been 
induced by an excessive optimism towards multimodal 
treatment, recruiting at the moment more advanced 
disease[36]. However, patients with N3b tumors do 
have a very scarce prognosis[37], although they are 
considered same as N3a in stage grouping. 
Dikken et al[38], testing latest TNM in prognostication 
of 2196 patients, found a decreased heterogeneity 
among stage groups, and observed that the increased 
complexity of the latest TNM is not accompanied 
by an improvement in prognostic accuracy of stage 
grouping. Regarding this aspect, Röcken et al[39] 
proposed to reduce to 3 groups (instead of 7) M0 
patients according to different combinations of the new 
T and N parameters: low risk group with > 60% 5-year 
survival rate, intermediate risk group with 20%-60% 
5-year survival rate and high risk group with < 20% 
5-year survival rate. 
Since stage grouping is essential in prognostication 
(not in treatment planning), hopefully summing the 
three parameters, it is probably here that great simpli-
city and high accuracy has to be reached.
CONCLUSION
Although many criticisms have been reported since 
seventh TNM classification was adopted, we may 
consider it a valuable tool in assessing the extent of 
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Table 1  Stage grouping based on cluster analysis in the 
International gastric cancer association stage grouping
N0 N1 N2 N3a N3b
T1 ⅠA ⅠB ⅡA ⅡB ⅢB1
T2 ⅠB ⅡA ⅡB ⅢA ⅢB1
T3 ⅡA ⅡB ⅢA ⅢB ⅢC1
T4a ⅡB ⅢA ⅢA1 ⅢB1 ⅢC
T4b ⅢA1 ⅢB ⅢB1 ⅢC ⅢC 
1Categories are different from 7th TNM grouping.
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